BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation

Andrew G. Li, Elizabeth C. Murphy, Aedin C. Culhane, Emily Powell, Hua Wang, Roderick T. Bronson, Thanh Von, Anita Giobbie-Hurder, Rebecca S. Gelman, Kimberly J. Briggs, Helen Piwnica-Worms, Jean J. Zhao, Andrew L. Kung, William G. Kaelin, David M. Livingston

Research output: Contribution to journalArticlepeer-review

Abstract

BRCA1 is an established breast and ovarian tumor suppressor gene that encodes multiple protein products whose individual contributions to human cancer suppression are poorly understood. BRCA1-IRIS (also known as "IRIS"), an alternatively spliced BRCA1 product and a chromatin-bound replication and transcription regulator, is overexpressed in various primary human cancers, including breast cancer, lung cancer, acute myeloid leukemia, and certain other carcinomas. Its naturally occurring overexpression can promote the metastasis of patient-derived xenograft (PDX) cells and other human cancer cells in mouse models. The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/ GSK-3β pathway leading to prolyl hydroxylase-independent HIF-1α stabilization and activation in a normoxic environment. Thus, despite the tumor-suppressing genetic origin of IRIS, its properties more closely resemble those of an oncoprotein that, when spontaneously overexpressed, can, paradoxically, drive human tumor progression.

Original languageEnglish
Pages (from-to)E9600-E9609
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number41
DOIs
Publication statusPublished - 9 Oct 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation'. Together they form a unique fingerprint.

Cite this